Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe so
Wish the dog survive long and keep doing great, can you help to connect with the owner? I am in the biopharma research field, very interested in supplements which can help fight diseases.
can you kindly post the link here?
I am living there not far actually, I will find time to drop by and see what they are doing now!
great messages
At close of market on Wednesday, NaturalShrimp Inc (OTCQB:SHMP) stock finished trading at +10.58%, bringing the stock price to $0.21 on the OTCQB – U.S. Registered. The stock price saw a low of $0.19 and a high of $0.23.
The company’s stock was traded 589 times with a total of 4,495,689 shares traded.
NaturalShrimp Inc has a market cap of $62.03 million, with 296.81 million shares in issue.
The company has been so quiet for a while. It could be something good.
We wait in patience, Radiogel needs to be tried in human cancer patients as soon as possible. RIGHT TO TRY policy should be applicable.
hope this comes soon. I hope to have powder to buy more in cheap.
these three catalysts will be coming one by one! 5M investment is the done deal, RS is on the way! 6th dog treatment was scheduled, others will be updated soon! Pilot clinics open soon hopefully with a partnership forged there!!!
yes, that is the News will land!RDGL will do it soon!!!
hold,hold,hold just for fighting against cancers, God bless us and America
no share available for cheap now, hold for good news even RS cancellation! who knows! The company is still working towards good direction!!~!
yes, that is right! no body wants to sell cheap, hold for next news soon!
hope news release soon, there is hope in this company
Solid evidences of how the patent and related techs and products from other companies actually based on the IP that brk company owned. Brk won the court settlement whick laid the foundation that brk will get partnerships and joint venture soon.
great greetings!Happy Easter, God bless those whose heart and soul belong to Him
yes, I believe, I read though the patent, and found it is quite unique, even there is some minor similarity but amendment would address it so patent will be good in hand soon.
good faith, I hope so too,
wish the patent will be granted soon, which will be huge
100% agree with you, Vivos is having critical turning point
https://www.facebook.com/pg/Mooses-Journey-Fighting-Canine-Soft-Tissue-Sarcoma-1839463746091221/posts/?ref=page_internal
Mooses owner replied a question about Mooses in above facebook page:
He is doing fine. The treated tumor site continues to heal. There will be no more testing until his yearly checkup.
great post, hope SHMP is doing well for near future
If you are a flipper, sell and leave if you do not like it! If you are long here, please have patience and respect to the people who actually work hard leading the company. The CEO has its strategy of doing it right, we will expect more news
that is really good News there, indicating the company is still in action.
The longer the quiet time is, probably the bigger news will be. Who knows, thanks to all the longs here to support!!!(:)
thank you friend for sharing your visit,how to schedule a visit there?I am interested in a tour there and taste the best shrimp.
agreed no more
I won't sell any of my shares because vivos has the product actually working well. Things will be getting better when RS finalized and an opening pilot animal clinics are known to the public.
Richland WA, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL)
Vivos Inc. (OTCPINK: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in animals and humans, provides this update on the dogs that were treated to date in the canine soft tissue sarcoma series.
IsoPet therapy is applied in a single therapy session. Most of the radiation dose is delivered within the first ten days as the Yttrium-90 decays. It then takes several months for the dead tumor to be absorbed by the animal. In general, sarcomas tend to be resistant to radiation and slow to respond to therapy but also prone to recurrence, so continued monitoring of these patients and future patients is critical.
Dog 1 was treated in May 2018. He had acute radiation side effects compounded by self-trauma (biting and scratching the tumor site), but achieved a CR (complete response) per the response evaluation criteria in solid tumors (RECIST) criteria and the normal tissues associated with the irradiation site appeared healthy. The patient was re-evaluated in February 2019 which included a CT scan. While the original tumor was destroyed, a recurrent tumor appeared which has been observed for sarcomas treated with other modalities including surgery and external beam radiation therapy (EBRT). Fortunately, the skin overlying the new tumor looks healthy and second therapy will be scheduled imminently.
Dog 2 which was treated in July 2018 and his results are encouraging. This patient had transient mild acute radiation side effects, and had SD (stable disease) at the time of recheck. There was a small amount of growth, but not enough to be considered progression per the RECIST criteria. The CT on his last visit showed that the tumor site had a slightly larger but diffuse image.
Based on this single observation, the diffuse image could mean that the hydrogel, in addition to trapping the particles, provides a secondary benefit of locking in the dead tumor tissue allowing for a slower rate of resorption of the necrotic tissue. This could be a positive outcome whereas killing a tumor and having it resorb within the tissue all at once might be a shock to the animal’s system. We will continue to monitor how this case proceeds.
Dog 3 was treated in January 2019. This very large, half-pound, tumor was initially scheduled for therapy in December but had to be rescheduled since the hydrogel did not meet our rigid specifications. From this, we learned that frozen hydrogel has a limited shelf life and this allowed us to make the appropriate adjustments to our product specifications.
This patient had mild to moderate acute radiation side effects and has SD (stable disease) one-month post treatment. The February follow-up included a CT scan. The mass showed no new growth and measures almost the same as it did at the time of treatment. There is a small region at the bottom of the tumor where the mass seems to be draining. The tumor around the highest dose region appears dead with no blood supply, according to the CT.
Dog 4 - We treated another animal for canine soft tissue sarcoma on February 21 and are awaiting a follow-up appointment for an examination of the dog
Dr. Mike Korenko, Vivos Inc CEO stated “IsoPet® is behaving as designed and the treatments applied thus far prove that it kills cancerous tumors. IsoPet® is minimally invasive compared to repeated surgeries, greatly spares normal tissue, and can achieve significantly higher dose than other therapies thereby increasing the probability of eradicating the disease. We will continue to generate new data via additional therapies at the University of Missouri. Following the canine soft tissue series, we plan to begin therapy of equine sarcoids, which are common in horses, but have limited options for effective treatment. Results of ongoing studies will be presented at premier scientific events such as the Veterinary Cancer Society annual meeting.”
truth and hope are here:
www.clippercorporatepartners.com/2019/02/vivos-slays-dragon-initially-posted.html
As most of you know, I have been a Corporate Advisor to Vivos inc. (RDGL) since October. When I began my service to the company, it was trying to claw its way out of a mess. In fact, it was probably days away from being bankrupt. That would have been a shame, because RDGL really does have a viable treatment for cancerous tumors. That has already been proven in at least two dogs and several cats.
Unfortunately, the company's future had been mortgaged through toxic debt. Vivos management doesn't like to point fingers (and we had quite an argument over this), but I will. The toxic debt was piled onto the company by former CEO, James Katzaroff, almost exclusively to pay the salaries of his wife and himself, as well as take a bunch of pointless and expensive trips to places like Russia, albeit purportedly for the company's benefit, but to no avail. The Katzaroffs had taken as much as a million dollars out of Vivos over the final few years of Jim's tenure as CEO. In contrast, current CEO, Dr. Mike Korenko, has deferred his salary until the company is viable, and in fact, has paid a lot of the company's bills with his own credit cards.
Under Jim Katzaroff, the company made very little progress while having its viability placed into jeopardy, all in the name of a paycheck. Katzaroff could have raised money under more responsible terms, but taking on toxic debt was easier and the simpler route to ensure he and his wife got paid. Toxic borrowing is almost always for the benefit of management, so that they are ensured that their pockets are lined--under the guise of salary and usually for doing nothing--without regard to the retail shareholder.
In short, Katzaroff was in breach of his fiduciary duties to Vivos.
For those that don't understand toxic debt, it is effectively a loan that is collateralized by the company's stock. This in itself is not necessarily an issue, however under a toxic (or death spiral) loan, the terms of the loan conversion are not fixed, but at a variable discount to the share price. So when a loan becomes due, the toxic lender converts a certain amount of his debt into stock which he promptly dumps into the market, almost always causing the share price to take a significant hit. Then he converts more of his loan into more stock--now at a cheaper price--immediately dumps it, and the share price takes another hit. And so on and so on. This is why it is called death spiral financing, because the share price will get killed into oblivion as an enormous amount of stock is created to satisfy the loan. All the while, the remaining principal continues to accrue interest.
Now consider that Katzaroff subjected Vivos to not one, but seven toxic lenders concurrently, having borrowed well over a million dollars, and with each lender fighting the other to dump stock faster. This is why the share price took a hit every time Vivos issued a good press release. Interest in Vivos was generated by the release, but the toxic lenders would take advantage of the increased buying volume by dumping more stock. It was like trying to climb out of a manhole with no ladder.
Why toxic lending is legal is beyond me, as it is usurious and will hurt the retail shareholder every time. But that is a topic for another time.
At the end of last summer, things were coming to a head for Vivos. Stuck under the thumb of the toxic lenders and unable to fund the company due to a spiraling share price, the company made a series of bold moves. One of them was hiring me as Corporate Advisor. They almost didn't. My aggressive, no nonsense style is very much in contrast to the demeanor of current management. By way of example, when Jim Katzaroff was fired, management chose to quietly come to terms through a Separation Agreement, where I would have sued the bastard for breach of fiduciary duty and fraud. Yes fraud, because the directors' signatures on Katzaroff's employment agreement were forged and the minutes of the directors meeting which were design to approve the agreement were concocted, i.e. it never happened. Anyway, when I came on board, it was essentially under two conditions: (1) things would be done the right way; and (2) the benefit of the shareholders would be a priority. Nobody is going to manipulate this company during my tenure.
Last autumn, Vivos was able to negotiate its way out from the remaining toxic debt, by converting the balance to common shares @ $.004/share. There was to be no more variable share conversion. This created about 1.2 billion new shares in one shot, and the toxic lenders still had about 200 million previously converted shares that were yet unsold. Under this Path Forward Agreement, the toxic lenders would be limited to selling no more than 15% of their holdings in any one month, whenever the share price was under $.01. This is why there was increased selling at the beginning of January and on Friday, February 1st. The toxic lenders were getting their 15% allotment onto the street.
The other critical goal that Vivos was able to accomplish last autumn, was the raising of about $750,000 in equity financing to get the company through to the end of the year. This was required to bring relief to the outstanding accounts payable and fund the treatment of the next couple of patients, as well as bring the Vista clinic online. Developing a treatment for a disease is an expensive endeavor, and the cost of materials is astronomical. The equity financing was accomplished @ $.005/share, creating 150 million new shares, and there is a restriction on trading of those share for a period of one year.
If not for the negotiated settlement of the debt of the toxic lenders and the raising of funds, Vivos would not be in business today. This is a fact. Vivos has indeed slayed the dragon.
So now we come to the reverse split.
Right now, there is approximately 2 billion shares issued and outstanding on a fully diluted basis. What's worse is that there is still about 500 million shares in the hands of the toxic lenders just waiting to be dumped. That only adds to the pressure on the share price. It is not the business model of toxic lenders to invest in companies, but to take advantage of those in dire straits and flip a quick profit. It is a testament to the accomplishments and future prospects of Vivos that the toxic lenders were prepared to negotiate a set price conversion of their debt to stock. This is unheard of within the penny stock market.
Vivos needs $5 million this year to continue development of RadioGel/IsoPet, open new clinics, and so on. To raise this money under the current share structure would require the issuance of at least 3 billion (restricted) new shares. Probably more. And then the share price would never get anywhere.
In order to get funding under more beneficial terms, Vivos needs to reduce the liquidity of the stock. This is going to require a reverse split. We spent weeks discussing this, as nobody wanted to subject the loyal retail shareholders (we don't care about flippers), to a reverse split. Then we agreed to the one for eight ratio because it would enable the shareholders to maintain a holding in the company, while reducing the selling pressure. In this way, the toxic lenders would be left with something over 60 million shares to sell, while limiting their selling to less than 10 million shares per month, a number that is more easily absorbed into the market.
Everyone knows that I hate reverse splits. But this is one that I believe will ultimately benefit the shareholders, because I believe that the share price will be better able to rise in the near term, and because Vivos will be able to obtain more equity funding under better terms. This is not a reverse split that wipes out the shareholders like many penny stock scams execute for the singular purpose of defrauding the public under a wash-rinse-repeat scenario (see my previous posts on CXBS).
This is a reverse split that keeps the shareholders well-being in mind. And for the record, the funders that provided the approximately $750,000 Vivos needed last autumn in exchange for stock that is restricted for one year, all pre-approved the reverse split. I insisted that we receive their approval because I felt it was unfair not to give them a voice on this course of action just three months after we took their money.
Issuing shares for financing is the cost of doing business. There isn't a public company out there, including the big companies, that doesn't dilute their stock in the name of progress, sometimes for acqusisitions, sometimes as compensation. This is why the A/S was not reduced by the same ratio as the O/S. At the end of the day, hopefully, the shareholder is left with a smaller piece of a bigger pie. As for finding development partners to take on some of the cost for a piece of ownership, that is indeed in the plan, once RadioGel/IsoPet have crossed certain thresholds.
When will the reverse split occur? Probably within a month. We have not filed the required paperwork yet, but felt that shareholders and pending shareholders had the right to know our plans as soon as they had been resolved upon by management. That is why we issued the press release on Friday. When I came on board, I insisted on complete transparency, and management agrees. At any rate, I expect that the Informational Filing will be completed in the coming week.
A word about the third dog which was recently treated with IsoPet. We have been getting a lot of questions about her status. We have not discussed her progress because the Doctors at the University of Missouri that have been performing the procedures have a policy regarding publicity that we have been admonished to follow (I think the words "or else" were implied). Therefore, Vivos has elected to follow their guidelines as to the release of information regarding a patient. We will release a progress report as soon as we can. All that having been said, I will remind you that as was stated in the December 4th press release, the patient is in an advanced state of disease and has a half pound tumor. This is outside of the scope of IsoPet's targeted patient qualifications. However, we agreed to treat her for humanitarian reasons and to discover any residual effect on metastasized cells in her body. Her prognosis was poor prior to her treatment.
And on a final note, a lot of people have been referring to RadioGel/IsoPet as a cure for cancer. This is simply not the case. It is a treatment for cancerous tumors, much like radiation is. In fact, RadioGel/IsoPet is a delivery system for radioactive isotopes to radiate the tumor much the same way that conventional therapies do, but without the damage to healthy cells. So far, RadioGel/IsoPet has been proven to be effective in the killing of treated cancerous tumors. However, much as in conventional radiation therapies, it does not mean that tumors will not reoccur.
Enjoy the Super Bowl.
Note: I wrote this blog post on my own accord and without the consent of Vivos management. While the facts are irrefutable, the company prefers to issue non-combatitive press releases, while I prefer to inform the public of the facts.
~ George
yes they have legit and approved product isopet for all kinds of solid tutors treatment for pets, that is why smart money of 5M wants in, after RS, this will go up high!!! Who knows if the partnership is emerging or not!
by this means, a better IR is needed. Longs here can work as ambassadors for the brkk to let it known by social media.
I am patiently waiting either. Hope patience gets to where the longs will be rewarded
I thought so, RS is the prerequisite for getting that 5M private replacement funding for the company operation this year and next year! hope the pilot clinics opening encourage the market and revenue generation. Then more successful treatments on animal patients by isopet will prove its effectiveness with rolling to human trials.
good point, hope it really is this case
can you share the link, please, thank you
Good, I am holding long with it, hopefully, really great news will come soon.
I learned from you, friend, probably patience is the key, luckily you got shares in low price, I guess this price possibly become history. hope get some shares like this low.
I had same situation as yours, having significant loss on paper, holding through these ups and downs. Hope see the light at end. this is undervalued for sure.
Richland WA, March 04, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma series.
Dr. Mike Korenko, Vivos Inc CEO stated “On February 25, 2019 we provided a detailed update on the status of dogs that have been treated to date with Y-90 IsoPet at the University of Missouri Center for Veterinary Medicine. Reporting results on therapies at the University of Missouri requires their review and approval. As a result, the last press release was technically accurate, but included terminology commonly used by veterinary professionals but not generally understood by the general public. For that reason, I believe that it is necessary to provide the following summary observations:
IsoPet® is easily administered in an outpatient setting using the procedures provided in the product labeling.
IsoPet® killed any cancer cells that came within the treatment zone.
Biologically it takes time for the dead tissue to resorb, but the rate and quality of normal tissue regeneration is encouraging.
I am confident that IsoPet extended the duration and quality of life of the patients that were treated.
I was particularly impressed that IsoPet effectively stopped the growth of a half-pound tumor.
IsoPet® is a great product and we are looking forward to making it available commercially.”
We as long time investors here has been suffering long time with Vivos, we need better IR to stand out and answer investors concerns and questions, too long silence won't do good for company unless the company really will release blow out news.
Well said, hope CEO read these words and get inspiration to do great things!
This is a good angle of thinking things in positive! Brkk is on the way of changing! CEO wants it to be big, two people are better than one!